Targeting the cardiohepatic-metabolic axis: GLP-1-based and incretin multi-agonist therapies in MASH

More on GLP-1 receptor agonists

• Diabetes, Obesity & Metabolism·4 Oct 2026

  GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

• Lancet·4 Oct 2026

  Orforglipron matches insulin glargine on cardiovascular safety

• Neurology Genetics·4 Oct 2026

  GLP-1 receptor agonists link to lower stroke and Alzheimer risk

• Frontiers in Nutrition·4 Oct 2026

  Cardiometabolic burden is linked to CVD and death in MASLD